Direkt zum InhaltDirekt zur SucheDirekt zur Navigation
▼ Zielgruppen ▼

Wirtschaft

Humboldt-Universität zu Berlin | Wirtschaft | WTT-Plattform: Förderungen, Kooperationsanfragen und Veranstaltungen | European Joint Programme on Rare Diseases (EJP RD) Call for Proposals 2020: "Pre-clinical research to develop effective therapies for rare diseases"

European Joint Programme on Rare Diseases (EJP RD) Call for Proposals 2020: "Pre-clinical research to develop effective therapies for rare diseases"

Pre-proposal submission deadline on 18 February 2020

Aim of the Call

The aim of the call is to enable scientists in different countries to build an effective collaboration on a common interdiscipinary research project based on complementaries and sharing of expertise, with a clear future benefit for patients.

 

Topic

Research proposals must cover at least one of the following areas: 

  1. Development of novel therapies in a preclinical setting focusing on condition(s) with unmet medical needs.
  2. Use of disease models suitable for medicinal product's development according to EMA guidelines.
  3. Development of predictive and pharmacodynamics (PD) biomarkers in a preclinical setting for monitoring the efficiency of the therapy. The model chosen must mimic the human diseases and be tranposable so that the biomarker identified in animals can be valid for humans.
  4. Proof of principle studie fostering an ealry stage of drug development. 

 

The following approaches and topics are exluded from the scope of the call:

  1. Therapeutic approaches concerning rare infectious diseases, rare cancers and rare adverse drug events in treatments of common diseases
  2. Interventional clinical trials
  3. Surgery or radiation therapies
  4. Studies that focus on research to accelerate diagnosis or to set up new registry/cohort studies to explore disease progression and mechanisms as these were the focus of JTC 2019.
  5. Rare neurodegenerative diseases which are within the main focus of the Joint Programming Initiative on Neurodegenerative Disease Research (JPND).   
    Childhood dementias/neurodegenerative diseases are not excluded.

 

Projects shall involve a group of rare diseases or a single rare disease following the European definition in the European Community, EC associated states and Canada. Applicants are encouraged to assemble groups of rare diseases based on solid criteria and commonalities if this leverages added value in sharing resources or expertise and has the capacity to elucidate common disease mechanisms and therapeutic targets.

Consortium Makeup

 

Partners belonging to one of the following categories may request funding under a joint research proposal (according to country/regional regulations):

  • academia 
  • clinical/public health sector 
  • enterprises. Participation of small and medium-sized enterprises (SMEs) is encouraged when allowed by national/regional regulations
  • patient advocacy organisations (PAOs are eligible to obtain funding for their participation in research projects)

The maximum duration of the project is three years.

Only transnational projects will be funded. Each consortium submitting a proposal must involve four to six eligible principal investigator partners. No more than two eligible partners from the same country can be present in each consortium (further national limits may apply). This limit applies to Early Career Researchers and partners from underrepresented countries (see below). PAOs requesting funding do not count toward this total.

The number of partners can be increased to 8 in two cases:

  • The inclusion of partners from participating countries usually underrepresented in projects (Czech Republic, Slovakia, Hungary, Lithuania, Poland, and Turkey).
  • The inclusion of Early Career Researchers as full partners.

 

More information will be published here.